Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C

Journal of Viral Hepatitis

Volumn 15, Issue 9, 2008, Pages 623-633

  Gambarin Gelwan, M ^a   Jacobson, I M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Genotype 1 non responders; Genotype 2; Hepatitis C; Induction dose pegylated interferon; Shorter duration therapy; Weight based dose ribavirin

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN;

CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RIBAVIRIN; UNITED STATES;

EID: 49649095896     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.01018.x     Document Type: Review

References (60)

1. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999 341 : 556 562.
2. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997 72 : 341 344.
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999 340 : 745 750.
4. Poynard T, Yuen MF, Ratziu V et al. Viral hepatitis C. Lancet 2003 362 : 2095 2100.
5. Hadziyannis SJ, Sette Jr H, Morgan TR et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
6. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trail. Lancet 2001 358 : 958 965.
7. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronci hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
8. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998 339 : 1485 1492.
9. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998 352 : 1426 1432.
10. Jacobson I, Brown R, Freilich B et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007 46 : 971 981.
11. Blatt LM, Mutchnick MG, Tong MJ et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 2000 7 : 196 202.
12. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990 12 : 1132 46.
13. Ning Q, Brown D, Parodo J et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl 2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998 160 : 3487 93.
14. Crotty S, Maag D, Arnold JJ et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000 6 (12 1375 1379.
15. Jacobson IM, Brown R, Freilich B et al. Response to peginterferon alfa-2b and ribavirin for chronic hepatitis C virus in patients with body weight >125 kg: results from WIN-R trial. Hepatology 2006 44 (Suppl. 328A.
16. Jacobson IM, Brown Jr RS, McCone J et al. Impact of weight-based ribavirin with Peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 2007 46 : 982 990.
17. Freilich B, Hu KQ, Jacobson I et al. Prospective analysis of sustained virologic response (SVR) to PEG-Interferon (PEG IFN) alfa-2B and ribavirin treatment in Asian and Hispanic patients with chronic hepatitis C: results from the WIN-R trial. Hepatology 2006 44 (Suppl. 320A.
18. Marotta P, Feinman SV, Ghent C et al. Final results of the Canadian POWeR (Peginterferon alfa-2B prospective Optimal Weight-based dosing Response) program. Sustained virologic response (SVR) to weight-based peginterferon alfa-2b + ribavirin in a large, mixed community and academic observational study (abstract). Hepatology 2007 46 (Suppl. 351A.
19. Feinman SV, Ghent C, Witt-Sullivan HB et al. Consistency of sustained virologic response (SVR) across weight categories: results from the Canadian POWeR (Peginterferon alfa-2B prospective Optimal Weight-based dosing Response) program (abstract). Hepatology 2007 46 (Suppl. 373A.
20. Shiffman ML, Salvatore J, Hubbard S et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007 46 : 371 379.
21. Lindhal K, Stahle L, Bruchfeld A et al. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005 41 : 275 279.
22. ®) in patients with "difficult-to-cure" characteristics (abstract). Hepatology 2006 44 (Suppl. 314A.
23. Reddy KR, Shiffman ML, Morgan TR et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007 5 (1 124 129.
24. US National Institutes of Health. A Randomized, Double-Blind Study of the Effect of PEGASYS and Ribavirin Combination Therapy on Viral Kinetics and Virologic Response in Interferon-naïve Patients With Chronic Hepatitis C Genotype 1 Infection (online). Available from URL: http://clinicaltrials.gov/ ct2/show/NCT00077649?term=peginterferon+and+ribavirin+and+hepatitis+c&cond= genotype+1&rank=27 (Accessed 29 March 2008).
25. Mimidis K, Papadopulos VP, Elefsiniotis I et al. Hepatitis C virus survival curve analysis in naïve patients treated with Peginterferon alfa-2b plus ribavirin. A randomized controlled trial for induction with high doses of Peginterferon and predictability of sustained viral response form early virologic data. J Gastrointestin Liver Dis 2006 13 : 213 219.
26. Roberts S, Weltman MD, Crawford D et al. Rapid and early virological response rates are increased with 12 week 360 μg/week peginterferon alfa-2a (40KD) and standard ribavirin in HCV genotype 1 treatment naïve patients: efficacy and safety analysis of the induction phase of the CHARIOT study. Hepatology 2007 46 (Suppl. 257A.
27. Schiffman ML, Di Bisceglie AM, Lindsay KL et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004 126 : 1015 1023.
28. 3 trials. Gastroenterology 2005 128 (Suppl. 2 A681.
29. Teuber G, Kallinowski B, Niederau C et al. Retreatment with pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C not responding to previous antiviral treatment with standard interferons combined with ribavirin. Gastroenterology 2003 124 (Suppl. 2 699.
30. Lawitz E, Bala N, Becker S et al. Peginterferon alfa-2b and ribavirin for hepatitis C patients who were nonresponders to previous therapy. Gastroenterology 2003 124 (Suppl. 2 A783.
31. Jacobson IM, Gonzales SA, Ahmed E et al. A randomized trial of pegylated interferon alfa-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005 100 : 2453 2462.
32. Taliani G, Gemignani G, Ferrari C et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology 2006 130 : 1098 1106.
33. Sherman M, Yoshida EM, Deschenes M et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006 55 : 1631 1638.
34. Gross J, Johnson S, Kwo P et al. Double-dose peginterferon alfa-2B with weight-based ribavirin improves response for interferon/ribavirin non-responders with hepatitis C: final results of "RENEW" (abstract). Hepatology 2005 42 (Suppl. 1 219A.
35. Bergmann JF, Vrolijk JM, van der Schaar P et al. γ- Glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-α-2b in chronic hepatitis C non-responders. Liver Int 2007 27 : 1217 1225.
36. Gaglio P, Choi J, Zimmerman D et al. Weight based ribavirin in combination with pegylated interferon alfa 2-B does not improve SVR in HCV infected patients who failed prior therapy: results in 454 patients. Hepatology 2005 42 (Suppl. 1 219A.
37. ®) for chronic hepatitis C patients who were non-responders (NR) or relapsers (R) to previous therapy (abstract). Hepatology 2005 42 (Suppl. 1 651A.
38. Jensen DM, Freilich B, Andreone P et al. Pegylated interferon alfa-2a (40 KD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12KD) / RBV: final efficacy and safety outcomes of the REPEAT study (abstract). Hepatology 2007 46 (Suppl. LB4.
39. ® in patients not responding to prior peginterferon alfa-2b/ribavirin (RBV) combination therapy - efficacy analysis of the 12-week induction period of the REPEAT study (abstract). Hepatology 2005 42 (Suppl. 1 749A.
40. Hezode C, Bouvier-Alias M, Roudot-Thoraval F et al. Efficacy and safety of peginterferon alfa-2a administered every five days in combination with ribavirin in HCV genotype-1 infected patients with severe fibrosis not responding to weekly administrations of peginterferon in combination with ribavirin (abstract). Hepatology 2006 44 (Suppl. 1 322A.
41. Hornfeldt E, Stahle L, Schvarcz R et al. Response to high ribavirin dose in combination with peg-IFN alfa-2a for treatment of HCV genotype 1 previous non-responders. Hepatology 2007 46 (Suppl. 350A.
42. Bacon B, Regev A, Ghalib RH et al. The DIRECT trial (Daily-dose consensus Interferon and Ribavirin: Efficacy of Combined Therapy): treatment of non-responders to previous pegylated interferon plus ribavirin: sustained virologic response data. Hepatology 2007 46 (Suppl. 311A.
43. Heathcote J, Main J. Treatment of hepatitis C. J Viral Hepat 2005 12 : 223 235.
44. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004 40 : 993 999.
45. Zeuzem S, Herrmann E, Lee JH et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha-2a. Gastroenterology 2001 120 : 1438 1447.
46. Neumann AU, Lam NP, Dahari H et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000 182 : 28 35.
47. Mangia A, Santoro R, Minerva N et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005 352 : 2609 2617.
48. Dalgard O, Mangia A. Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection. Drugs 2006 66 : 1807 1815.
49. Dalgard O, Bjoro K, Hellum KB et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004 40 : 1260 1265.
50. VonWagner M, Huber M, Berg T et al. Peginterferon alfa-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterol 2001 120 : 1438 1447.
51. Mecenate F, Barbaro G, Pellicelli A et al. Comparison of peginterferon alfa-2a and ribavirin for 12 and 24 weeks in patients with HCV genotype 2 or 3: the CLEO trial. Hepatology 2007 46 (Suppl. 828A.
52. Yu ML, Dai CY, Huang JF et al. A randomized study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007 56 : 553 559.
53. Shiffman ML, Suter F, Bacon BR et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007 357 : 124 134.
54. ®) for 16 or 24 weeks (abstract). Hepatology 2006 44 (Suppl. 333A.
55. Powis J, Peltekian KM, Lee SS et al. (Canadian Pegasys Study Group). Exploring differences in response to treatment with peginterferon alfa 2a (40KD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat 2008 15 : 52 57.
56. Dalgard O, Bjoro K, Ring-Larsen H et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virologic response. Hepatology 2008 47 : 35 43.
57. Liang TJ. Shortened therapy for hepatitis C virus genotype 2 or 3 - is less more? N Engl J Med 2007 357 : 176 178.
58. US National Institutes of Health. Comparison of Three Regimens of PEG-Intron and Ribavirin in the Treatment of Chronic Hepatitis C, Genotype 2 or 3, in Previously Untreated Patients (online). Available from URL: http://clinicaltrials.gov/ct2/show/record/NCT00302081?term= hcv+and+genotype+2+or+3&rank=5 (accessed 20 January 2008).
59. Willems B, Hadziyannis SJ, Morgan TR et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virological response? J Hepatol 2007 46 (Suppl. 1 S6.
60. US National Institutes of Health. A Randomized, Open-Label Study of the Effects of 24 vs 48 Weeks of Combination Therapy With PEGASYS (Peginterferon Alfa-2a 40KD) Plus COPEGUS (Ribavirin) on Sustained Virological Response in Patients With Chronic Hepatitis C, Genotype 2 or 3 Who do Not Achieve a Rapid Viral Response (online). Available form URL: http://clinicaltrials.gov/ct2/show/ NCT00623428?term=hepatitis+c+genotype+2+or+3&rank=3 (accessed 26 March 2008).